Posted by Michael Wonder on 09 Dec 2020
Most favoured nation drug pricing rule will harm patient access and jeopardise practice stability, rheumatology leaders warn
9 December 2020 - The American College of Rheumatology today warned that the CMS interim final rule establishing a “most favoured nation” payment model for Medicare Part B drugs will dramatically disrupt patient access to critical therapies needed to manage rheumatic diseases and conditions.
Further, the rule threatens the financial solvency of many rheumatology practices – particularly those located in rural and underserved areas, including those that have been hardest hit by the COVID-19 pandemic – and jeopardises the ability of rheumatologists to provide treatments to patients most in need.
